Business Description
Baxter International Inc
NAICS : 339112
SIC : 3841
ISIN : US0718131099
Share Class Description:
BAX: Ordinary SharesCompare
Compare
Traded in other countries / regions
BAX.USA0QK8.UKBTL.GermanyBAX.Austria1BAX.ItalyBAX.MexicoB1AX34.BrazilBAX.Switzerland IPO Date
1961-05-15Description
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter has signed an agreement to sell its kidney care tools by early 2025.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.11 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 1.68 | |||||
| Debt-to-EBITDA | 8.65 | |||||
| Interest Coverage | 1.3 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.11 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9 | |||||
| 3-Year EBITDA Growth Rate | -9 | |||||
| 3-Year FCF Growth Rate | -3.1 | |||||
| 3-Year Book Growth Rate | -1.3 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 8.89 | |||||
| 9-Day RSI | 18.83 | |||||
| 14-Day RSI | 24.65 | |||||
| 3-1 Month Momentum % | -17.85 | |||||
| 6-1 Month Momentum % | -3.29 | |||||
| 12-1 Month Momentum % | -13.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.23 | |||||
| Days Inventory | 87.38 | |||||
| Days Sales Outstanding | 51.07 | |||||
| Days Payable | 37.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.43 | |||||
| Dividend Payout Ratio | 0.78 | |||||
| 3-Year Dividend Growth Rate | 6.7 | |||||
| Forward Dividend Yield % | 2.24 | |||||
| 5-Year Yield-on-Cost % | 5.52 | |||||
| 3-Year Average Share Buyback Ratio | -0.2 | |||||
| Shareholder Yield % | 24.22 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 33.42 | |||||
| Operating Margin % | 3.21 | |||||
| Net Margin % | 0.63 | |||||
| FCF Margin % | 2.26 | |||||
| ROE % | 1.34 | |||||
| ROA % | 0.39 | |||||
| ROIC % | 3.18 | |||||
| 3-Year ROIIC % | -13.45 | |||||
| ROC (Joel Greenblatt) % | 3.11 | |||||
| ROCE % | 1.06 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 151.6 | |||||
| Forward PE Ratio | 12.12 | |||||
| PE Ratio without NRI | 20.43 | |||||
| Shiller PE Ratio | 10.19 | |||||
| PS Ratio | 0.89 | |||||
| PB Ratio | 1.97 | |||||
| Price-to-Free-Cash-Flow | 39.48 | |||||
| Price-to-Operating-Cash-Flow | 14.52 | |||||
| EV-to-EBIT | 118.5 | |||||
| EV-to-Forward-EBIT | 14.3 | |||||
| EV-to-EBITDA | 17.87 | |||||
| EV-to-Forward-EBITDA | 9.21 | |||||
| EV-to-Revenue | 1.58 | |||||
| EV-to-Forward-Revenue | 2.01 | |||||
| EV-to-FCF | 69.71 | |||||
| Price-to-GF-Value | 0.88 | |||||
| Price-to-Projected-FCF | 0.9 | |||||
| Price-to-Median-PS-Value | 0.29 | |||||
| Earnings Yield (Greenblatt) % | 0.84 | |||||
| FCF Yield % | 2.53 | |||||
| Forward Rate of Return (Yacktman) % | 11.43 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers